Services Articles
A scientific hub to keep you informed about our latest research and company updates.
Personalized Lymphoma CDX mouse models for preclinical oncology
Modelling TDP-43 proteinopathy and motor neuron disease pathophysiology in mouse models
InnoSer and Carthera Launch Preclinical Access to the SonoCloud® Ultrasound Platform for CNS Drug Delivery
Neurofilament light chain (NfL) in plasma and CSF: A translational biomarker for neurodegeneration in InnoSer’s neurology mouse models
New insights into TDP-43 mouse model pathophysiology
InnoSer and CureSHANK partner to launch industry-quality preclinical testing service for Phelan-McDermid syndrome (PMS) treatments
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
InnoSer Partners with Kabuki Syndrome Foundation to Advance Therapeutic Development for Kabuki Syndrome
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research
info@innoserlaboratories.com